Other authors have confirmed that sparing IL-4 in the selective blockade of interleukin-13 in patients treated with tralokinumab leads to a smaller Th2/Th1 immune switch and a lower incidence of conjunctivitis compared to those treated with dupilumab [52,53]. This evidence concerns the gene IL13 and conjunctivitis.